Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis
Daniel Victor Ortigoza, Vice Chair of the Argentine Federation of Cardiology’s Cardio-Oncology Committee, shared on LinkedIn about a recent article by Gilles Montalescot et al, published in JACC, adding:
”Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy. Gilles Montalescot, MD, PHD, et al. J Am Coll Cardiol Intv 2022;15:1794–1804)
A prospective, controlled, open-label, randomized clinical trial in post-TAVR patients comparing apixaban versus standard treatment, evaluated using 4D CT and cardiac Doppler echocardiography.
762 patients evaluated with 4D CT and then randomized 1:1
The aim was to determine whether the DOAC prevents the formation of small thrombi on the implanted valve.
Apixaban reduced subclinical thrombosis (8.9% vs. 13%) but did not demonstrate significant clinical improvements (death, myocardial infarction, or stroke)
Classification of the degree of thrombosis detected by 4D C:
HALT – hypoattenuated leaflet thickening
RLM – reduced leaflet motion.”
Title: Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy
Authors: Gilles Montalescot, Alban Redheuil, Flavien Vincent, Steffen Desch, Mauro De Benedictis, Hélène Eltchaninoff, Dietmar Trenk, Jean-Michel Serfaty, Etienne Charpentier, Khaoula Bouazizi, Mikael Prigent, Paul Guedeney, Tomy Salloum, Sergio Berti, Angel Cequier, Thierry Lefèvre, Pascal Leprince, Johanne Silvain, Eric Van Belle, Franz-Josef Neumann, Jean-Jacques Portal, Eric Vicaut, Jean-Philippe Collet

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series